Innovent Biologics Announces Strategic Collaboration with Roche to Advance Multiple Tumor Cell Therapies and Bispecific Antibodies

Suzhou, June 9, 2020 /PRNewswire/ -- Innovent Biologics (Stock Code on the Hong Kong Stock Exchange: 01801)，A biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for the treatment of major diseases such as cancer, metabolic disorders, and autoimmune diseases, today announced a strategic R&D collaboration with Roche, covering multiple oncology cell therapies and bispecific antibodies.

The collaboration between the two parties will focus on the research, clinical development, and commercialization of multiple bispecific antibody and cell therapy products, which will be directly used for the treatment of hematologic malignancies and solid tumors.

Under the terms of the collaboration, Innovent Bio will make certain upfront payments, development and commercial milestone payments, and product sales royalties to Roche for the use of Roche’s technology in developing 2:1 bispecific T-cell engager antibodies and a universal CAR-T platform. Innovent Bio will be responsible for the research and development, manufacturing, and commercialization of these products. Roche retains an exclusive option to repurchase the rights to develop and commercialize these products outside of China.IfRoche ExercisesAll of itOption,thenPayment to Innovent BioTotalA $140 million upfront payment, andIf all products are successfully developed and commercialized, milestone payments totaling approximately $1.96 billion for product development, approval, and commercialization,In additionIt will also pay a double-digit percentage sales commission for each product.

Dr. Yu Dexiao, Founder, Chairman, and CEO of Innovent Bio, stated, “Innovent Bio began its strategic deployment in cell therapy several years ago. This strategic collaboration with Roche marks a significant step forward in the development of our cell therapy discovery platform. Leveraging Roche’s proprietary innovative universal CAR-T technology, we will strengthen and broaden our presence in the field of cell therapy. Furthermore, by capitalizing on Roche’s platform advantages in 2:1 T-cell bispecific antibodies, we will discover, develop, and commercialize novel bispecific molecules, thereby consolidating and expanding our portfolio of innovative bispecific antibody products. This strategic partnership is highly exciting. We will utilize the technological strengths under this collaborative framework to advance the development of these products in China, while Roche retains the option for development outside of China. We hope to provide more effective innovative therapies to patients worldwide.”

About Innovent Bio

“Rooted in Trust, Realized through Action.” It is Innovent Bio’s vision and goal to develop high-quality biologics that are affordable to the general public. Established in 2011, Innovent Bio is dedicated to the development, manufacturing, and commercialization of innovative medicines for the treatment of major diseases such as cancer, metabolic disorders, and autoimmune diseases. On October 31, 2018, Innovent Biologics (Suzhou) Co., Ltd. was listed on the Main Board of The Stock Exchange of Hong Kong Limited, with stock code: 01801.

Since its establishment, the company has stood out among numerous biopharmaceutical companies by virtue of its innovative achievements and internationalized operating model. It has built a product pipeline comprising 23 new drug candidates, covering multiple disease areas including oncology, metabolic diseases, and autoimmune disorders. Among these, six candidates were selected for the National “Major New Drug Development” Special Project, 17 have entered clinical studies, five have reached Phase III or pivotal clinical trials, and marketing applications for four monoclonal antibody products have been accepted by the NMPA, with three granted priority review status. One product (Sintilimab Injection, brand name: Tyvyt^®, English trademark: TYVYT^®) received NMPA approval for market launch, with the first approved indication being relapsed/refractory classical Hodgkin lymphoma, and in November 2019, it became the only PD-1 inhibitor included in the new version of the National Reimbursement Drug List.

Innovent Bio has assembled a world-class team of experts in the development and industrialization of high-end biologics, including numerous overseas-returning specialists. The company has established strategic collaborations with international partners such as Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, and Hanmi Pharmaceutical. Innovent Bio is committed to working collectively to advance China’s biopharmaceutical industry, thereby enhancing drug accessibility for the public and fulfilling people’s aspirations for better health and well-being. For more details, please visit the company’s website:www.innoventbio.com。